Pathology & Oncology Research

, 15:473 | Cite as

Expression of EphA2 and E-cadherin in Gastric Cancer: Correlated with Tumor Progression and Lymphogenous Metastasis

  • Weijie Yuan
  • Zhikang Chen
  • Shaobin Wu
  • Jie Ge
  • Shi Chang
  • Xianwei Wang
  • Jingxiang Chen
  • Zihua Chen
Original Paper

Abstract

In this study, gastric cancer progression was correlated with the over-expression of erythropoietin-producing hepatocellular (Eph)A2 receptor and down-expression of epithelial cadherin (E-cadherin). Immunohistochemistry of EphA2 and E-cadherin were performed on these tumor samples from 165 primary lesions of gastric cancer. The results showed that expression of EphA2 was obviously increased in gastric cancer tissues (P < 0.01), which was positively correlated with the depth of cancer invasion, tumor-node-metastasis (TNM) stage and lymph node metastasis (P < 0.05). Meanwhile, the expression of E-cadherin was significantly reduced (P < 0.01), which was negatively correlated with the depth of cancer invasion, grade of tumor differentiation, TNM stage and lymph node metastasis (P < 0.05). The correlation between EphA2 and E-cadherin expression was negative (r = −0.198, P = 0.011). In conclusion, either the over-expression of EphA2 or the down-expression of E-cadherin is correlated with cancer progression and lymphogenous metastasis in gastric cancer, suggesting that both of them may play an important role in tumor progression and metastasis.

Keywords

EphA2 E-cadherin Gastric cancer Immunohistochemistry 

Abbreviations

Eph

erythropoietin-producing hepatocellular

E-cadherin

epithelial cadherin

RTK

receptor tyrosine kinase

PBS

phosphate buffered solution

DAB

diaminobenzidine tetrachloride

TNM

tumor-node-metastasis

MMP

matrix metalloprotease

References

  1. 1.
    Catalano V, Labianca R, Beretta GD et al (2005) Gastric cancer. Crit Rev Oncol Hematol 54:209–241CrossRefPubMedGoogle Scholar
  2. 2.
    Dicken BJ, Bigam DL, Cass C et al (2005) Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 241:27–39PubMedGoogle Scholar
  3. 3.
    Sulman EP, Tang XX, Allen C et al (1997) ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics 40:371–374CrossRefPubMedGoogle Scholar
  4. 4.
    Walker-Daniels J, Hess AR, Hendrix MJC et al (2003) Differential regulation of EphA2 in normal and malignant cells. Am J Pathol 162:1037–1042PubMedGoogle Scholar
  5. 5.
    Miyazaki T, Kato H, Fukuchi M et al (2003) EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 103:657–663CrossRefPubMedGoogle Scholar
  6. 6.
    Zeng G, Hu Z, Kinch MS et al (2003) High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 163:2271–2276PubMedGoogle Scholar
  7. 7.
    Kinch MS, Moore MB, Harpole DH et al (2003) Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9:613–618PubMedGoogle Scholar
  8. 8.
    Han L, Dong Z, Qiao Y et al (2005) The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol Oncol 99:278–286CrossRefPubMedGoogle Scholar
  9. 9.
    Abraham S, Knapp DW, Cheng L et al (2006) Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 12:353–360CrossRefPubMedGoogle Scholar
  10. 10.
    Bussemakers MJ, van Bokhoven A, Mees SG et al (1993) Molecular cloning and characterization of the human E-cadherin cDNA. Mol Biol Rep 17:123–128CrossRefPubMedGoogle Scholar
  11. 11.
    Takeichi M (1993) Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 5:806–811CrossRefPubMedGoogle Scholar
  12. 12.
    Chen H, Paradies NE, Fedor-Chaiken M et al (1997) E-cadherin mediates adhesion and suppresses cell motility via distinct mechanisms. J Cell Sci 110:345–356PubMedGoogle Scholar
  13. 13.
    Hazan RB, Qiao R, Keren R et al (2004) Cadherin switch in tumor progression. Ann NY Acad Sci 1014:155–163CrossRefPubMedGoogle Scholar
  14. 14.
    Zantek ND, Azimi M, Fedor-Chaiken M et al (1999) E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 10:629–638PubMedGoogle Scholar
  15. 15.
    Thaker PH, Deavers M, Celestino J et al (2004) EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 10:5145–5150CrossRefPubMedGoogle Scholar
  16. 16.
    Lin YG, Han LY, Kamat AA et al (2007) EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 109:332–340CrossRefPubMedGoogle Scholar
  17. 17.
    Shiozaki H, Tahara H, Oka H et al (1991) Expression of immunoreactive E-cadherin adhesion molecule in human cancer. Am J Pathol 139:17–23PubMedGoogle Scholar
  18. 18.
    Jawhari A, Jordan S, Poole S et al (1997) Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology 112:46–54CrossRefPubMedGoogle Scholar
  19. 19.
    Zhou Y, Ran J, Tang C (2007) Effect of celecoxib on E-cadherin, VEGF, Microvessel density and apoptosis in gastric cancer. Cancer Biol Ther 6:269–275CrossRefPubMedGoogle Scholar
  20. 20.
    Sobin LH, Wittekind CH (eds) (1997) TNM Classification of Malignant Tumors, 5th edn. Wiley, New YorkGoogle Scholar
  21. 21.
    Ogawa K, Pasqualini R, Lindberg RA et al (2000) The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19:6043–6052CrossRefPubMedGoogle Scholar
  22. 22.
    Zelinski DP, Zantek ND, Stewart JC et al (2001) EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61:2301–2306PubMedGoogle Scholar
  23. 23.
    Fang WB, Brantley-Sieders DM, Parker MA et al (2005) A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 24:7859–7868CrossRefPubMedGoogle Scholar
  24. 24.
    Lu C, Shahzad MM, Wang H et al (2008) EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 7:1–6CrossRefGoogle Scholar
  25. 25.
    Zantek ND, Walker-Daniels J, Stewart J et al (2001) MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin Cancer Res 7:3640–3648PubMedGoogle Scholar
  26. 26.
    Kinch MS, Carles-Kinch K (2003) Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis 20:59–68CrossRefPubMedGoogle Scholar
  27. 27.
    Kikawa KD, Vidale DR, Van Etten RL et al (2002) Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J Biol Chem 277:39274–39279CrossRefPubMedGoogle Scholar
  28. 28.
    Parri M, Buricchi F, Taddei ML et al (2005) EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase. J Biol Chem 280:34008–34018CrossRefPubMedGoogle Scholar
  29. 29.
    Chen HC, Chu RY, Hsu PN et al (2003) Loss of E-cadherin expression correlates with poor differentiation and invasion into adjacent organs in gastric adenocarcinomas. Cancer Lett 201:97–106CrossRefPubMedGoogle Scholar
  30. 30.
    Lee KH, Shin SJ, Kim KO et al (2006) Relationship between E-cadherin, matrix metalloproteinase-7 gene expression and clinicopathological features in gastric carcinoma. Oncol Rep 16:823–830PubMedGoogle Scholar
  31. 31.
    Guilford PJ, Hopkins JB, Grady WM et al (1999) E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat 14:249–255CrossRefPubMedGoogle Scholar
  32. 32.
    Tamura G, Yin J, Wang S et al (2000) E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 92:569–573CrossRefPubMedGoogle Scholar
  33. 33.
    Koizume S, Tachibana K, Sekiya T et al (2002) Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells. Nucleic Acids Res 30:4770–4780CrossRefPubMedGoogle Scholar
  34. 34.
    Catimel B, Layton M, Church N et al (2006) In situ phosphorylation of immobilized receptors on biosensor surfaces: application to E-cadherin/beta-catenin interactions. Anal Biochem 357:277–288CrossRefPubMedGoogle Scholar
  35. 35.
    Noë V, Fingleton B, Jacobs K et al (2001) Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114:111–118PubMedGoogle Scholar
  36. 36.
    Rios-Doria J, Day KC, Kuefer R et al (2003) The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. J Biol Chem 278:1372–1379CrossRefPubMedGoogle Scholar
  37. 37.
    Saito T, Masuda N, Miyazaki T et al (2004) Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. Oncol Rep 11:605–611PubMedGoogle Scholar
  38. 38.
    Orsulic S, Kemler R (2000) Expression of Eph receptors and ephrins is differentially regulated by E-cadherin. J Cell Sci 113:1793–1802PubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2008

Authors and Affiliations

  • Weijie Yuan
    • 1
  • Zhikang Chen
    • 1
  • Shaobin Wu
    • 1
  • Jie Ge
    • 1
  • Shi Chang
    • 1
  • Xianwei Wang
    • 1
  • Jingxiang Chen
    • 1
  • Zihua Chen
    • 1
  1. 1.Department of General Surgery, Xiangya HospitalCentral South UniversityChangshaPeoples Republic of China

Personalised recommendations